These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8549382)

  • 1. Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
    Kawahara S; Watanabe Y; Matsuka Y; Sato T; Takahashi K
    Drugs; 1995; 49 Suppl 2():414-5. PubMed ID: 8549382
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
    Watanabe K; Yoshida M; Ishibashi T; Yamada H; Kido M; Hirose T; Maeda F; Matsuzaki Y
    Drugs; 1995; 49 Suppl 2():448-50. PubMed ID: 8549396
    [No Abstract]   [Full Text] [Related]  

  • 3. Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.
    Sufarlan AW; Zainudin BM; Pit S; Ishak I
    Drugs; 1995; 49 Suppl 2():442-5. PubMed ID: 8549394
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 5. Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin.
    Stocks JM; Wallace RJ; Griffith DE; Garcia JG; Kohler RB
    Am J Med; 1989 Dec; 87(6C):52S-56S. PubMed ID: 2690620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin in patients with severe respiratory tract infection.
    Odagiri S
    Drugs; 1995; 49 Suppl 2():426-7. PubMed ID: 8549387
    [No Abstract]   [Full Text] [Related]  

  • 7. Additive effect of continuous low dose ofloxacin on erythromycin therapy for sinobronchial syndrome.
    Fujimura M; Ishiura Y; Saito M; Shibata K; Nomura M; Nakatsumi Y; Matsuda T
    Drugs; 1995; 49 Suppl 2():409-11. PubMed ID: 8549380
    [No Abstract]   [Full Text] [Related]  

  • 8. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections.
    Sato A; Ogawa H; Iwata M; Ono T; Yasuda K; Nagayama M; Shirai T; Shirai M; Ida M; Suda T
    Drugs; 1995; 49 Suppl 2():428-9. PubMed ID: 8549388
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections.
    Sawae Y; Ninomiya K; Takaki K; Shimono N; Misumi H; Okada K
    Drugs; 1995; 49 Suppl 2():430-2. PubMed ID: 8549390
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
    Peugeot RL; Lipsky BA; Hooton TM; Pecoraro RE
    Drugs Exp Clin Res; 1991; 17(5):253-7. PubMed ID: 1756688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of ofloxacin versus cefazolin in lower respiratory tract infections.
    Bariffi F; Giacomelli P; Sanduzzi A; Perna F; De Masi AL
    Int J Clin Pharmacol Res; 1987; 7(3):199-201. PubMed ID: 3474212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of the new quinolones in lower respiratory infections.
    Davies BI; Maesen FP
    Chemioterapia; 1987 Jun; 6(2 Suppl):447-8. PubMed ID: 3509469
    [No Abstract]   [Full Text] [Related]  

  • 14. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of ofloxacin in lower respiratory tract infections bacteriologically diagnosed by fibreoptic-bronchoscopy aspirate culture.
    Tomasic-Cvitanovic S; Kotaraki Z
    Drugs; 1995; 49 Suppl 2():446-7. PubMed ID: 8549395
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
    Shishido H; Furukawa K; Nagai H; Kawakami K; Kono H
    Drugs; 1995; 49 Suppl 2():433-5. PubMed ID: 8549391
    [No Abstract]   [Full Text] [Related]  

  • 17. Ofloxacin in lower respiratory tract infections.
    Hänninen P
    Drugs; 1987; 34 Suppl 1():179-80. PubMed ID: 3481320
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of quinolones in respiratory tract infections.
    Maesen FP; Davies BI; Geraedts WH; Baur C
    Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation.
    Liam CK; Aziah AM; Lim KH; Wong CM
    Med J Malaysia; 2000 Sep; 55(3):304-7. PubMed ID: 11200708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.